Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Comment by snootchybootchyon Mar 14, 2017 5:13pm
118 Views
Post# 25978769

RE:RE:RE:ARLZ will be discounted to cash

RE:RE:RE:ARLZ will be discounted to cash
kuatolives wrote: Goldman sold half his stake this morning. What a bozo. He's as bad a trader as he is a "Pharma exec" who, for some reason, thought it was a good idea to wipe out his shareholders by trading steady growth for a massive single bet - that didn't pan out. I wonder if he realizes how much damage he's done A) with his actions at Trbute, and B) selling this pig to investors with this articles (I was a victim of A)

Anyway, one last risk to consider is if Deerfield decides to pull the plug on the credit line.


I'm shocked to hear this.  Isn't he on the board?  If he sold, it means he doesn't see much hope for Yosprala.  Isn't it way too early to sound the death knell for a new drug?  It hasn't even been six months yet.  I've read about lots of drugs that slowly gains traction after a disappointing launch.  There are other drugs that have much stronger uptake in Europe than in North America. 
<< Previous
Bullboard Posts
Next >>